July 27 (Reuters) – China-based Innocare Pharma said on Monday the Phase III trial of fadeucravacitinib, an experimental treatment for moderate-to-severe plaque psoriasis, has met its primary endpoint.
The company plans to advance the regulatory filing process for fadeucravacitinib (ICP-488) following the completion of the study, it added.
(Reporting by Shivangi Lahiri in Bengaluru; Editing by Vijay Kishore)
